The tweet was deleted by the author.
But we saved everything 🙂.
Humacyte is engaging with the vascular medical community this spring by participating in several regional and national meetings.
The company will showcase its portfolio, including the Symvess and acellular tissue engineered vessel-tyod (ATEV), highlighting the benefits of its ready-off-the-shelf, human-derived vascular solutions. These initiatives underscore Humacyte's commitment to advancing innovative options for vascular surgery and patient care. Details are being clarified.
Humacyte recently secured at least $1.475 million for Symvess vessel sales supporting a clinical program in Saudi Arabia, according to a company announcement. The company has also filed for Israeli approval of its Symvess acellular tissue-engineered vessel as an option for urgent arterial repair, as stated in a previous disclosure. Both initiatives expand the international reach of Humacyte's vascular portfolio.